{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,5,27]],"date-time":"2024-05-27T23:41:09Z","timestamp":1716853269222},"reference-count":62,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2014,6,25]],"date-time":"2014-06-25T00:00:00Z","timestamp":1403654400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Urologe"],"published-print":{"date-parts":[[2014,7]]},"DOI":"10.1007\/s00120-014-3535-z","type":"journal-article","created":{"date-parts":[[2014,6,23]],"date-time":"2014-06-23T10:39:04Z","timestamp":1403519944000},"page":"1031-1039","update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Aktive \u00dcberwachung beim Niedrigrisikoprostatakarzinom","Active surveillance of low risk prostate cancer"],"prefix":"10.1007","volume":"53","author":[{"given":"K.","family":"Lellig","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"B.","family":"Beyer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"Graefen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"D.","family":"Zaak","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C.","family":"Stief","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2014,6,25]]},"reference":[{"key":"3535_CR1","unstructured":"Robert Koch-Institut (2010) Prostatakrebs. http:\/\/www.krebsdaten.de\/Krebs\/DE\/Content\/Krebsarten\/Prostatakrebs\/prostatakrebs_node.html"},{"key":"3535_CR2","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1016\/j.eururo.2013.09.046","volume":"65","author":"Heidenreich","year":"2014","unstructured":"Heidenreich A, Bastian PJ, Bellmunt J et al (2014) EAU guidelines on prostate cancer. Part 1: screening, diagnosis, and local treatment with curative intent-update 2013. Eur Urol 65:124\u2013137","journal-title":"Eur Urol"},{"key":"3535_CR3","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1016\/S0022-5347(05)67373-9","volume":"164","author":"Hoedemaeker","year":"2000","unstructured":"Hoedemaeker RF, Rietbergen JB, Kranse R et al (2000) Histopathological prostate cancer characteristics at radical prostatectomy after population based screening. J Urol 164:411\u2013415","journal-title":"J Urol"},{"key":"3535_CR4","doi-asserted-by":"crossref","first-page":"2106","DOI":"10.1016\/j.juro.2007.03.003","volume":"177","author":"Thompson","year":"2007","unstructured":"Thompson I, Thrasher JB, Aus G et al (2007) Guideline for the management of clinically localized prostate cancer: 2007 update. J Urol 177:2106\u20132131","journal-title":"J Urol"},{"key":"3535_CR5","doi-asserted-by":"crossref","first-page":"2529","DOI":"10.1001\/archinte.1993.00410220025003","volume":"153","author":"Dorr","year":"1993","unstructured":"Dorr VJ, Williamson SK, Stephens RL (1993) An evaluation of prostate-specific antigen as a screening test for prostate cancer. Arch Intern Med 153:2529\u20132537","journal-title":"Arch Intern Med"},{"key":"3535_CR6","doi-asserted-by":"crossref","first-page":"1650","DOI":"10.1002\/cncr.23373","volume":"112","author":"Dall","year":"2008","unstructured":"Dall\u2019Era MA, Cooperberg MR, Chan JM et al (2008) Active surveillance for early-stage prostate cancer: review of the current literature. Cancer 112:1650\u20131659","journal-title":"Cancer"},{"key":"3535_CR7","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1016\/j.eururo.2013.02.024","volume":"64","author":"Van","year":"2013","unstructured":"Van Den Bergh RC, Albertsen PC, Bangma CH et al (2013) Timing of curative treatment for prostate cancer: a systematic review. Eur Urol 64:204\u2013215","journal-title":"Eur Urol"},{"key":"3535_CR8","doi-asserted-by":"crossref","first-page":"2172","DOI":"10.1002\/(SICI)1097-0142(19981115)83:10<2172::AID-CNCR16>3.0.CO;2-K","volume":"83","author":"D","year":"1998","unstructured":"D\u2019amico AV, Desjardin A, Chen MH et al (1998) Analyzing outcome-based staging for clinically localized adenocarcinoma of the prostate. Cancer 83:2172\u20132180","journal-title":"Cancer"},{"key":"3535_CR9","doi-asserted-by":"crossref","first-page":"2407","DOI":"10.1016\/S0022-5347(01)62200-6","volume":"160","author":"Epstein","year":"1998","unstructured":"Epstein JI, Chan DW, Sokoll LJ et al (1998) Nonpalpable stage T1c prostate cancer: prediction of insignificant disease using free\/total prostate specific antigen levels and needle biopsy findings. J Urol 160:2407\u20132411","journal-title":"J Urol"},{"key":"3535_CR10","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1097\/MOU.0b013e32835f8f6b","volume":"23","author":"Klotz","year":"2013","unstructured":"Klotz L (2013) Active surveillance: patient selection. Curr Opin Urol 23:239\u2013244","journal-title":"Curr Opin Urol"},{"key":"3535_CR11","unstructured":"Lepor H, Donin NM (2014) Gleason 6 prostate cancer: serious malignancy or toothless lion? Oncology (Williston Park) 28:16\u201322"},{"key":"3535_CR12","doi-asserted-by":"crossref","first-page":"933","DOI":"10.1002\/1097-0142(19930201)71:3+<933::AID-CNCR2820711408>3.0.CO;2-L","volume":"71","author":"Stamey","year":"1993","unstructured":"Stamey TA, Freiha FS, McNeal JE et al (1993) Localized prostate cancer. Relationship of tumor volume to clinical significance for treatment of prostate cancer. Cancer 71:933\u2013938","journal-title":"Cancer"},{"key":"3535_CR13","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/j.juro.2010.08.082","volume":"185","author":"Wolters","year":"2011","unstructured":"Wolters T, Roobol MJ, Van Leeuwen PJ et al (2011) A critical analysis of the tumor volume threshold for clinically insignificant prostate cancer using a data set of a randomized screening trial. J Urol 185:121\u2013125","journal-title":"J Urol"},{"key":"3535_CR14","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1097\/MOU.0b013e32835f97e9","volume":"23","author":"Klotz","year":"2013","unstructured":"Klotz L (2013) Active surveillance: current and future directions. Curr Opin Urol 23:237\u2013238","journal-title":"Curr Opin Urol"},{"key":"3535_CR15","doi-asserted-by":"crossref","first-page":"1298","DOI":"10.1016\/S0022-5347(05)00646-4","volume":"175","author":"Freedland","year":"2006","unstructured":"Freedland SJ, Kane CJ, Amling CL et al (2006) Delay of radical prostatectomy and risk of biochemical progression in men with low risk prostate cancer. J Urol 175:1298\u20131302 (discussion 1302\u20131293)","journal-title":"J Urol"},{"key":"3535_CR16","doi-asserted-by":"crossref","first-page":"2095","DOI":"10.1001\/jama.293.17.2095","volume":"293","author":"Albertsen","year":"2005","unstructured":"Albertsen PC, Hanley JA, Fine J (2005) 20-year outcomes following conservative management of clinically localized prostate cancer. JAMA 293:2095\u20132101","journal-title":"JAMA"},{"key":"3535_CR17","doi-asserted-by":"crossref","first-page":"1202","DOI":"10.1001\/jama.2009.1348","volume":"302","author":"Lu-Yao","year":"2009","unstructured":"Lu-Yao GL, Albertsen PC, Moore DF et al (2009) Outcomes of localized prostate cancer following conservative management. JAMA 302:1202\u20131209","journal-title":"JAMA"},{"key":"3535_CR18","doi-asserted-by":"crossref","first-page":"1361","DOI":"10.1038\/sj.bjc.6603105","volume":"94","author":"Parker","year":"2006","unstructured":"Parker C, Muston D, Melia J et al (2006) A model of the natural history of screen-detected prostate cancer, and the effect of radical treatment on overall survival. Br J Cancer 94:1361\u20131368","journal-title":"Br J Cancer"},{"key":"3535_CR19","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1038\/bjc.2013.268","volume":"109","author":"De","year":"2013","unstructured":"De Camargo Cancela M, Comber H, Sharp L (2013) Age remains the major predictor of curative treatment non-receipt for localised prostate cancer: a population-based study. Br J Cancer 109:272\u2013279","journal-title":"Br J Cancer"},{"key":"3535_CR20","doi-asserted-by":"crossref","first-page":"2001","DOI":"10.1002\/cncr.20586","volume":"101","author":"Bastian","year":"2004","unstructured":"Bastian PJ, Mangold LA, Epstein JI et al (2004) Characteristics of insignificant clinical T1c prostate tumors. A contemporary analysis. Cancer 101:2001\u20132005","journal-title":"Cancer"},{"key":"3535_CR21","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1002\/cncr.23610","volume":"113","author":"Chun","year":"2008","unstructured":"Chun FK, Haese A, Ahyai SA et al (2008) Critical assessment of tools to predict clinically insignificant prostate cancer at radical prostatectomy in contemporary men. Cancer 113:701\u2013709","journal-title":"Cancer"},{"key":"3535_CR22","doi-asserted-by":"crossref","first-page":"1732","DOI":"10.1016\/j.juro.2012.07.024","volume":"188","author":"Vargas","year":"2012","unstructured":"Vargas HA, Akin O, Afaq A et al (2012) Magnetic resonance imaging for predicting prostate biopsy findings in patients considered for active surveillance of clinically low risk prostate cancer. J Urol 188:1732\u20131738","journal-title":"J Urol"},{"key":"3535_CR23","doi-asserted-by":"crossref","first-page":"956","DOI":"10.1111\/j.1464-410X.2009.08887.x","volume":"105","author":"Van","year":"2010","unstructured":"Van Den Bergh RC, Vasarainen H, Van Der Poel HG et al (2010) Short-term outcomes of the prospective multicentre \u201aProstate Cancer Research International: active surveillance\u2018 study. BJU Int 105:956\u2013962","journal-title":"BJU Int"},{"key":"3535_CR24","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1097\/MOU.0000000000000055","volume":"24","author":"Klotz","year":"2014","unstructured":"Klotz L, Emberton M (2014) Management of low risk prostate cancer: active surveillance and focal therapy. Curr Opin Urol 24:270\u2013279","journal-title":"Curr Opin Urol"},{"key":"3535_CR25","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1016\/S0022-5347(05)64053-0","volume":"169","author":"San","year":"2003","unstructured":"San Francisco IF, Dewolf WC, Rosen S et al (2003) Extended prostate needle biopsy improves concordance of Gleason grading between prostate needle biopsy and radical prostatectomy. J Urol 169:136\u2013140","journal-title":"J Urol"},{"key":"3535_CR26","doi-asserted-by":"crossref","first-page":"860","DOI":"10.1016\/j.juro.2007.05.016","volume":"178","author":"Griffin","year":"2007","unstructured":"Griffin CR, Yu X, Loeb S et al (2007) Pathological features after radical prostatectomy in potential candidates for active monitoring. J Urol 178:860\u2013863 (discussion 863)","journal-title":"J Urol"},{"key":"3535_CR27","doi-asserted-by":"crossref","first-page":"976","DOI":"10.1016\/j.eururo.2012.05.072","volume":"62","author":"Dall","year":"2012","unstructured":"Dall\u2019era MA, Albertsen PC, Bangma C et al (2012) Active surveillance for prostate cancer: a systematic review of the literature. Eur Urol 62:976\u2013983","journal-title":"Eur Urol"},{"key":"3535_CR28","doi-asserted-by":"crossref","unstructured":"Pokorny MR, De Rooij M, Duncan E et al (2014) Prospective study of diagnostic accuracy comparing prostate cancer detection by transrectal ultrasound-guided biopsy versus magnetic resonance (MR) imaging with subsequent MR-guided biopsy in men without previous prostate Biopsies. Eur Urol. DOI: 10.1016\/j.eururo.2014.03.002","DOI":"10.1016\/j.eururo.2014.03.002"},{"key":"3535_CR29","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1097\/MOU.0b013e32835ad3ee","volume":"23","author":"Marks","year":"2013","unstructured":"Marks L, Young S, Natarajan S (2013) MRI-ultrasound fusion for guidance of targeted prostate biopsy. Curr Opin Urol 23:43\u201350","journal-title":"Curr Opin Urol"},{"key":"3535_CR30","doi-asserted-by":"crossref","unstructured":"Mozer P, Roupret M, Le Cossec C et al (2014) First round of targeted biopsies with magnetic resonance imaging\/ultrasound-fusion images compared to conventional ultrasound-guided trans-rectal biopsies for the diagnosis of localised prostate cancer. BJU Int. DOI: 10.1111\/bju.12690","DOI":"10.1111\/bju.12690"},{"key":"3535_CR31","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1038\/pcan.2009.64","volume":"13","author":"Robinson","year":"2010","unstructured":"Robinson K, Creed J, Reguly B et al (2010) Accurate prediction of repeat prostate biopsy outcomes by a mitochondrial DNA deletion assay. Prostate Cancer Prostatic Dis 13:126\u2013131","journal-title":"Prostate Cancer Prostatic Dis"},{"key":"3535_CR32","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/j.eururo.2013.01.023","volume":"64","author":"Klotz","year":"2013","unstructured":"Klotz L (2013) Active surveillance, quality of life, and cancer-related anxiety. Eur Urol 64:37\u201339","journal-title":"Eur Urol"},{"key":"3535_CR33","doi-asserted-by":"crossref","first-page":"2810","DOI":"10.1200\/JCO.2009.25.7311","volume":"28","author":"Ross","year":"2010","unstructured":"Ross AE, Loeb S, Landis P et al (2010) Prostate-specific antigen kinetics during follow-up are an unreliable trigger for intervention in a prostate cancer surveillance program. J Clin Oncol 28:2810\u20132816","journal-title":"J Clin Oncol"},{"key":"3535_CR34","doi-asserted-by":"crossref","first-page":"1656","DOI":"10.1016\/j.juro.2010.12.042","volume":"185","author":"Whitson","year":"2011","unstructured":"Whitson JM, Porten SP, Hilton JF et al (2011) The relationship between prostate specific antigen change and biopsy progression in patients on active surveillance for prostate cancer. J Urol 185:1656\u20131660","journal-title":"J Urol"},{"key":"3535_CR35","doi-asserted-by":"crossref","first-page":"872","DOI":"10.1111\/j.1464-410X.2008.08116.x","volume":"103","author":"Ng","year":"2009","unstructured":"Ng MK, Van As N, Thomas K et al (2009) Prostate-specific antigen (PSA) kinetics in untreated, localized prostate cancer: PSA velocity vs PSA doubling time. BJU Int 103:872\u2013876","journal-title":"BJU Int"},{"key":"3535_CR36","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1016\/j.eururo.2012.02.002","volume":"62","author":"Bul","year":"2012","unstructured":"Bul M, Zhu X, Rannikko A et al (2012) Radical prostatectomy for low-risk prostate cancer following initial active surveillance: results from a prospective observational study. Eur Urol 62:195\u2013200","journal-title":"Eur Urol"},{"key":"3535_CR37","doi-asserted-by":"crossref","first-page":"1232","DOI":"10.1111\/j.1464-410X.2010.09589.x","volume":"107","author":"Dall","year":"2011","unstructured":"Dall\u2019era MA, Cowan JE, Simko J et al (2011) Surgical management after active surveillance for low-risk prostate cancer: pathological outcomes compared with men undergoing immediate treatment. BJU Int 107:1232\u20131237","journal-title":"BJU Int"},{"key":"3535_CR38","doi-asserted-by":"crossref","first-page":"1672","DOI":"10.1111\/j.1464-410X.2012.11434.x","volume":"110","author":"Bul","year":"2012","unstructured":"Bul M, Van Den Bergh RC, Zhu X et al (2012) Outcomes of initially expectantly managed patients with low or intermediate risk screen-detected localized prostate cancer. BJU Int 110:1672\u20131677","journal-title":"BJU Int"},{"key":"3535_CR39","doi-asserted-by":"crossref","first-page":"1573","DOI":"10.1002\/pros.22507","volume":"72","author":"Iremashvili","year":"2012","unstructured":"Iremashvili V, Manoharan M, Rosenberg DL et al (2012) Pathological findings at radical prostatectomy in patients initially managed by active surveillance: a comparative analysis. Prostate 72:1573\u20131579","journal-title":"Prostate"},{"key":"3535_CR40","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/j.juro.2013.01.019","volume":"190","author":"Satkunasivam","year":"2013","unstructured":"Satkunasivam R, Kulkarni GS, Zlotta AR et al (2013) Pathological, oncologic and functional outcomes of radical prostatectomy following active surveillance. J Urol 190:91\u201395","journal-title":"J Urol"},{"key":"3535_CR41","doi-asserted-by":"crossref","first-page":"3868","DOI":"10.1002\/cncr.24446","volume":"115","author":"Van","year":"2009","unstructured":"Van Den Bergh RC, Essink-Bot ML, Roobol MJ et al (2009) Anxiety and distress during active surveillance for early prostate cancer. Cancer 115:3868\u20133878","journal-title":"Cancer"},{"key":"3535_CR42","doi-asserted-by":"crossref","first-page":"588","DOI":"10.1016\/j.urology.2010.10.039","volume":"77","author":"Gorin","year":"2011","unstructured":"Gorin MA, Soloway CT, Eldefrawy A et al (2011) Factors that influence patient enrollment in active surveillance for low-risk prostate cancer. Urology 77:588\u2013591","journal-title":"Urology"},{"key":"3535_CR43","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1093\/jncimonographs\/lgs026","volume":"2012","author":"Bergman","year":"2012","unstructured":"Bergman J, Litwin MS (2012) Quality of life in men undergoing active surveillance for localized prostate cancer. J Natl Cancer Inst Monogr 2012:242\u2013249","journal-title":"J Natl Cancer Inst Monogr"},{"key":"3535_CR44","doi-asserted-by":"crossref","first-page":"1032","DOI":"10.1111\/j.1464-410X.2011.10846.x","volume":"110","author":"Van","year":"2012","unstructured":"Van Den Bergh RC, Korfage IJ, Roobol MJ et al (2012) Sexual function with localized prostate cancer: active surveillance vs radical therapy. BJU Int 110:1032\u20131039","journal-title":"BJU Int"},{"key":"3535_CR45","doi-asserted-by":"crossref","first-page":"2664","DOI":"10.1016\/j.juro.2009.08.044","volume":"182","author":"Fujita","year":"2009","unstructured":"Fujita K, Landis P, McNeil BK et al (2009) Serial prostate biopsies are associated with an increased risk of erectile dysfunction in men with prostate cancer on active surveillance. J Urol 182:2664\u20132669","journal-title":"J Urol"},{"key":"3535_CR46","doi-asserted-by":"crossref","first-page":"744","DOI":"10.1016\/j.juro.2013.08.054","volume":"191","author":"Braun","year":"2014","unstructured":"Braun K, Ahallal Y, Sjoberg DD et al (2014) Effect of repeated prostate biopsies on erectile function in men on active surveillance for prostate cancer. J Urol 191:744\u2013749","journal-title":"J Urol"},{"key":"3535_CR47","doi-asserted-by":"crossref","first-page":"969","DOI":"10.1001\/jama.280.11.969","volume":"280","author":"D","year":"1998","unstructured":"D\u2019Amico AV, Whittington R, Malkowicz SB et al (1998) Biochemical outcome after radical prostatectomy, external beam radiation therapy, or interstitial radiation therapy for clinically localized prostate cancer. JAMA 280:969\u201374","journal-title":"JAMA"},{"key":"3535_CR48","doi-asserted-by":"crossref","first-page":"1520","DOI":"10.1097\/01.ju.0000118224.54949.78","volume":"171","author":"Patel","year":"2004","unstructured":"Patel MI, DeConcini DT, Lopez-Corona E et al (2004) An analysis of men with clinically localized prostate cancer who deferred definitive therapy. J Urol 171:1520\u20131524","journal-title":"J Urol"},{"key":"3535_CR49","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1111\/j.1464-410X.2007.07190.x","volume":"101","author":"Soloway","year":"2008","unstructured":"Soloway MS, Soloway CT, Williams S (2008) Active surveillance; a reasonable management alternative for patients with prostate cancer: the Miami experience. BJU Int 101:165\u2013169","journal-title":"BJU Int"},{"key":"3535_CR50","doi-asserted-by":"crossref","first-page":"1297","DOI":"10.1016\/j.eururo.2008.02.039","volume":"54","author":"van","year":"2008","unstructured":"van As NJ, Norman AR, Thomas K (2008) Predicting the probability of deferred radical treatment for localised prostate cancer managed by active surveillance. Eur Urol 54:1297\u2013305","journal-title":"Eur Urol"},{"key":"3535_CR51","doi-asserted-by":"crossref","first-page":"2185","DOI":"10.1200\/JCO.2010.32.8112","volume":"29","author":"Tosoian","year":"2011","unstructured":"Tosoian JJ, Trock BJ, Landis P (2011) Active surveillance program for prostate cancer: an update of the Johns Hopkins experience. J Clin Oncol 29:2185\u20132190","journal-title":"J Clin Oncol"},{"key":"3535_CR52","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1200\/JCO.2009.24.2180","volume":"28","author":"Klotz","year":"2010","unstructured":"Klotz L, Zhang L, Lam A (2010) Clinical results of long-term follow-up of a large, active surveillance cohort with localized prostate cancer. J Clin Oncol 28:126\u2013131","journal-title":"J Clin Oncol"},{"key":"3535_CR53","doi-asserted-by":"crossref","unstructured":"Cooperberg MR, Carroll PR, Klotz L (2011) Active surveillance for prostate cancer: progress and promise. J Clin Oncol. 29:3669\u20133676","DOI":"10.1200\/JCO.2011.34.9738"},{"key":"3535_CR54","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.eururo.2008.09.007","volume":"55","author":"van","year":"2009","unstructured":"van den Bergh RC, Roemeling S, Roobol MJ et al (2009) Outcomes of men with screen-detected prostate cancer eligible for active surveillance who were managed expectantly. Eur Urol 55:1\u20138","journal-title":"Eur Urol"},{"key":"3535_CR55","doi-asserted-by":"crossref","first-page":"1964","DOI":"10.1016\/j.juro.2008.07.051","volume":"180","author":"Berglund","year":"2008","unstructured":"Berglund RK, Masterson TA, Vora KC et al (2008) Pathological upgrading and up staging with immediate repeat biopsy in patients eligible for active surveillance. J Urol 180:1964\u20131967","journal-title":"J Urol"},{"key":"3535_CR56","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1016\/j.eururo.2010.08.027","volume":"58","author":"Soloway","year":"2010","unstructured":"Soloway MS, Soloway CT, Eldefrawy A (2010) Careful selection and close monitoring of low-risk prostate cancer patients on active surveillance minimizes the need for treatment. Eur Urol 58:831\u2013835","journal-title":"Eur Urol"},{"key":"3535_CR57","doi-asserted-by":"crossref","first-page":"2359","DOI":"10.1016\/j.juro.2007.08.039","volume":"178","author":"Carter","year":"2007","unstructured":"Carter HB, Kettermann A, Warlick C (2007) Expectant management of prostate cancer with curative intent: an update of the Johns Hopkins experience. J Urol 178:2359\u20132364","journal-title":"J Urol"},{"key":"3535_CR58","doi-asserted-by":"crossref","first-page":"8165","DOI":"10.1200\/JCO.2005.03.3134","volume":"23","author":"Klotz","year":"2005","unstructured":"Klotz L (2005) Active surveillance for prostate cancer: for whom? J Clin Oncol 23:8165\u20138169","journal-title":"J Clin Oncol"},{"key":"3535_CR59","doi-asserted-by":"crossref","first-page":"1520","DOI":"10.1097\/01.ju.0000118224.54949.78","volume":"171","author":"Patel","year":"2004","unstructured":"Patel MI, DeConcini DT, Lopez-Corona E et al (2004) An analysis of men with clinically localized prostate cancer who deferred definitive therapy. J Urol 171:1520\u20131524","journal-title":"J Urol"},{"key":"3535_CR60","doi-asserted-by":"crossref","first-page":"956","DOI":"10.1111\/j.1464-410X.2005.05446.x","volume":"95","author":"Hardie","year":"2004","unstructured":"Hardie C, Parker C, Norman A et al (2004) Early outcomes of active surveillance for localized prostate cancer. BJU Int 95:956\u2013960","journal-title":"BJU Int"},{"key":"3535_CR61","doi-asserted-by":"crossref","first-page":"1244","DOI":"10.1016\/j.eururo.2006.11.053","volume":"51","author":"Roemeling","year":"2007","unstructured":"Roemeling S, Roobol MJ, de Vries SH et al (2007) Active surveillance for prostate cancers detected in three subsequent rounds of a screening trial: characteristics, PSA doubling times, and outcome. Eur Urol 51:1244\u20131250","journal-title":"Eur Urol"},{"key":"3535_CR62","doi-asserted-by":"crossref","unstructured":"Ercole B, Marietti SR, Fine J, Albertsen PC (2008) Outcomes following active surveillance of men with localized prostate cancer diagnosed in the prostate specific antigen era. J Urol180:1336\u20131339","DOI":"10.1016\/j.juro.2008.06.027"}],"container-title":["Der Urologe"],"original-title":[],"language":"de","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00120-014-3535-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00120-014-3535-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00120-014-3535-z","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,5,27]],"date-time":"2024-05-27T23:20:04Z","timestamp":1716852004000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00120-014-3535-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,6,25]]},"references-count":62,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2014,7]]}},"alternative-id":["3535"],"URL":"https:\/\/doi.org\/10.1007\/s00120-014-3535-z","relation":{},"ISSN":["0340-2592","1433-0563"],"issn-type":[{"value":"0340-2592","type":"print"},{"value":"1433-0563","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,6,25]]}}}